EXPERIENCE OF THE USE OF DEFERASIROX IN PAEDIATRIC PATIENTS WITH TRANSFUSIONAL DEPENDENCY

被引：0
|
作者：
Faci Cristina, Martinez [1 ]
Sanjuan Laura, Murillo [1 ]
Cebrian Flor, Yus [2 ]
Maria Angeles, Montanes Gracia [2 ]
Flores Maria Del Valle, Recasens [2 ]
Iturrate Carmen, Rodriguez-Vigil [1 ]
机构：
[1] Hosp Univ Miguel Servet, Serv Pediat, Zaragoza, Spain
[2] Hosp Univ Miguel Servet, Serv Hematol, Zaragoza, Spain
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PC-320
引用
收藏
页码：265 / 265
页数：1
相关论文
共 50 条
  • [31] Assessment of non-transferrin bound iron in patients with myelodisplastic syndrome and transfusional iron overload treated with deferasirox
    Del Orbe, R.
    Arrizabalaga, B.
    Zamora, M.
    Etxeguren, I.
    Olivares, M.
    Aragues, P.
    Erkiaga, S.
    Cantelli, B.
    Urresola, A.
    Collado, R.
    LEUKEMIA RESEARCH, 2013, 37 : S107 - S107
  • [32] Is Deferasirox Safe and Effective in Very Elderly Patients (> 75 Years) with Myelodysplastic Syndromes and Transfusional Iron Overload?
    Latagliata, Roberto
    Niscola, Pasquale
    Volpe, Antonio
    Barate, Claudia
    Campagna, Alessia
    Poloni, Antonella
    Sarlo, Chiara
    Faglioni, Laura
    De Benedictis, Daniela
    Carmosino, Ida
    Fenu, Susanna
    Spiriti, Maria Antonietta Aloe
    Galimberti, Sara
    Breccia, Massimo
    Foa, Robin
    Finelli, Carlo
    BLOOD, 2017, 130
  • [33] Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study
    Elalfy, Mohsen
    Inusa, Baba
    Beneitez, David
    Xicoy, Blanca
    Nieto, Maria Soledad Duran
    Bruederle, Andreas
    Azmon, Amin
    El-Beshlawy, Amal
    BLOOD, 2016, 128 (22)
  • [34] Comparative pharmacokinetic/pharmacodynamic profiles in Japanese and Caucasian patients with transfusional hemosiderosis ReceivingTreatment with deferasirox (Exjade®, ICL670).
    Iki, S.
    Urabe, A.
    Hata, T.
    Ohyashiki, K.
    Nakao, S.
    Takatoku, M.
    Ishikawa, T.
    Kato, J.
    Tatsumi, Y.
    Mori, H.
    Tanii, H.
    Taniguchi, J.
    Kondo, M.
    Schran, H.
    Rabault, B.
    BLOOD, 2006, 108 (11) : 296B - 297B
  • [35] GROWTH AND DEVELOPMENT OF PAEDIATRIC PATIENTS WITH BETATHALASSAEMIA TREATED WITH DEFERASIROX FOR UP TO 5 YEARS
    Aydinok, Y.
    Agaoglu, L.
    Bejaoui, M.
    Canatan, D.
    Drelichman, G.
    Economou, M.
    Fattoum, S.
    Kattamis, A.
    Kilinc, Y.
    Perrotta, S.
    Griffel, L.
    Lagrone, D.
    Clark, J.
    Cappellini, M. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 429 - 429
  • [36] Two-Year Analysis of Efficacy and Safety of Deferasirox Treatment for Transfusional Iron Overload in Sickle Cell Anemia Patients
    Cancado, Rodolfo
    Olivato, Maria Cristina A.
    Bruniera, Paula
    Szarf, Gilberto
    Bastos, Roberto de Moraes
    Melo, Murilo Rezende
    Chiattone, Carlos
    ACTA HAEMATOLOGICA, 2012, 128 (02) : 113 - 118
  • [37] Deferasirox (Exjade®, ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients
    Kattamis, C
    Kilinc, Y
    Fattoum, S
    Ferster, A
    Gallisai, D
    Maggio, A
    Dresse, MF
    Klingebiel, T
    Bourantas, K
    Canatan, D
    Maseruka, H
    Gathmann, I
    Ford, J
    BLOOD, 2005, 106 (11) : 756A - 756A
  • [38] NEPHROLITHIASIS IN CHRONICALLY TRANSFUSED PATIENTS SECONDARY TO DEFERASIROX USE
    Chan, Joshua
    Khodak, Igor
    Weinblatt, Mark
    Bhaumik, Sucharita
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [39] Deferasirox for the Treatment of Transfusional Iron Overload in Sickle Cell Anemia. Preliminary Results
    Cancado, Rodolfo D.
    Olivato, Maria Cristina A.
    Bruniera, Paula
    Chiattone, Carlos
    BLOOD, 2008, 112 (11) : 992 - 992
  • [40] Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome
    Escudero-Vilaplana, V.
    Garcia-Gonzalez, X.
    Osorio-Prendes, S.
    Romero-Jimenez, R. M.
    Sanjurjo-Saez, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (01) : 59 - 63
12345